ArticleJAC-antimicrobial resistance2025
Evaluating the effectiveness of low-dose oral switch therapy for uncomplicated streptococcal or enterococcal bloodstream infection: a retrospective cohort study.
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although oral switch therapy (OST) is increasingly recognized as a viable option for uncomplicated gram-positive bloodstream infections (GP-BSI), its optimal dosage remains unclear. In Japan, high-dose regimens of key oral antimicrobials, such as amoxicillin (1000 mg thrice daily) or levofloxacin (750 mg once daily), are not approved. This study investigated the effectiveness of low-dose OST for GP-BSI in a population with a low prevalence of obesity. Methods: This retrospective, single-centre study involved patients aged ≥18 years with monomicrobial, uncomplicated BSI caused by ampicillin- or amoxicillin-susceptible Results: A total of 172 patients (86 with OST and 86 with IVT only) were included. The median body mass index was 22.5 (interquartile range [IQR], 19.2-24.7), and the median duration of therapy was 14 days (IQR, 12-15 days). Common oral regimens included amoxicillin ( Conclusions: Low-dose OST may be effective for clinically stable patients with uncomplicated GP-BSI in settings with low obesity prevalence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.